简介：　　 [摘要 ] 目的 研究晚期结肠癌与直肠癌化疗近期有效率的差异。方法 共收集复发转移性大肠癌患者 194例，其中结肠癌患者 94例，直肠癌患者 100例，采用 χ2检验的方法对比分析两组患者经 4周期一线姑息性化疗后的疗效差异，以 P<0.05为标准。 结果 直肠癌患者化疗有效（ CR+PR） 38例（ 38.00%）。结肠癌患者中化疗有效（ CR+PR） 52例（ 55.32%）。两组患者化疗有效率差异有统计学意义（ P<0.05）。结论 晚期结肠癌患者姑息化疗近期有效率优于直肠癌组。  　　 [关键词 ] 晚期结肠癌；直肠癌；姑息化疗；差异  [Abstract] Objective To study the difference of short-term response rate between advanced colorectal cancer and rectal cancer. Methods a total of 194 patients with recurrent and metastatic colorectal cancer were collected, including 94 patients with colon cancer and 100 patients with rectal cancer. χ 2 test was used to compare and analyze the therapeutic effect of the two groups after four cycles of first-line palliative chemotherapy, with P < 0.05 as the standard. Results 38 patients (38.00%) had Cr + pr. Among the patients with colon cancer, 52 (55.32%) had effective chemotherapy (Cr + PR). There was significant difference in the effective rate of chemotherapy between the two groups (P < 0.05). Conclusion the short-term effective rate of palliative chemotherapy in patients with advanced colorectal cancer is better than that in patients with rectal cancer.

简介：

简介：　　 【摘要】 目的：观察贝伐珠单抗用于治疗非小细胞癌（ NSCLC）的临床效果及治疗后肿瘤标志物的变化。方法：选择 2018年 8月 -2019年 8月笔者所在医院肿瘤科、呼吸内科收治的 NSCLC患者 60例，随机分为观察组和对照组，各 30例，对照组予以培美曲塞、顺铂化疗，疗程为 3个化疗周期，每个化疗周期为 21 d;观察组在对照组化疗方案基础上加用贝伐珠单抗，疗程相同。比较两组血管内皮生长因子（ VEGF）、癌胚抗原（ CEA）、神经元特异性烯醇化酶（ NSE）水平，生活质量评分，不良反应发生情况。结果：治疗后，观察组患者 VEGF、 CEA、 NSE水平均较对照组低，差异有统计学意义（ P<0.05）。治疗后观察组患者生活质量评分在疼痛、食欲、呼吸困难、疲劳方面均优于对照组，差异有统计学意义（ P<0.05）。观察组不良反应发生率为 10.0%，对照组不良反应发生率为 26.7%，两组比较差异有统计学意义（ P<0.05）。结论：贝伐珠单抗治疗 NSCLC可使患者肿瘤指标下降，疗效确切且不增加患者化疗毒副作用，应作为新一代抗血管肿瘤药物作为一线应用，以为患者带来更大获益。  　　 【关键词】 贝伐珠单抗 ; 非小细胞癌 ; 肿瘤标志物 ; 抗血管生成  　 [Abstract] Objective: To observe the clinical effect of bevacizumab in the treatment of non-small cell carcinoma (NSCLC) and the changes of tumor markers after treatment. Methods: from August 2018 to August 2019, 60 NSCLC patients in the oncology department and Respiratory Department of our hospital were randomly divided into the observation group and the control group, 30 cases in each group. The control group was treated with pemetrexed and cisplatin for three chemotherapy cycles, each chemotherapy cycle for 21 days; the observation group was treated with bevacizumab on the basis of the control group chemotherapy scheme, with the same treatment course. The levels of VEGF, CEA, NSE, quality of life and adverse reactions were compared between the two groups. Results: after treatment, the levels of VEGF, CEA and NSE in the observation group were lower than those in the control group (P < 0.05). After treatment, the quality of life score of the observation group was better than that of the control group in pain, appetite, dyspnea and fatigue (P < 0.05). The incidence of adverse reactions was 10.0% in the observation group and 26.7% in the control group. Conclusion: Bevacizumab can reduce the tumor index of NSCLC patients, and the curative effect is exact without increasing the side effects of chemotherapy. It should be used as a new generation of anti-vascular tumor drugs as a first-line application, so as to bring greater benefits to the patients.